Anika to Exhibit its HA-Based Bone Repair Therapy at the 2019 American Orthopaedic Society for Sports Medicine Annual Meeting
July 11 2019 - 8:00AM
Business Wire
Anika Therapeutics, Inc. (NASDAQ: ANIK), a global,
integrated orthopedics and regenerative medicines company
specializing in therapeutics based on its proprietary
hyaluronic acid ("HA") technology, today announced
plans to exhibit its injectable, HA-based, surgical bone repair
therapy at the 2019 American Orthopaedic Society for Sports
Medicine (AOSSM) Annual Meeting being held July 11-14 in Boston,
Massachusetts at the Hynes Convention Center.
“We’re excited to attend this year’s AOSSM Annual Meeting and
showcase our HA-based bone repair therapy, which we will be
launching in the U.S. this quarter,” said Joseph Darling, President
and Chief Executive Officer of Anika Therapeutics. “We look forward
to continuing to build awareness around this innovative new therapy
and discussing its benefits with leading U.S. physicians in the
field of sports medicine.”
The AOSSM Annual Meeting focuses on providing information on
frontline research to the orthopedic sports medicine community,
allowing attendees to meet, educate and connect with top physicians
in the field of sports medicine. Nearly 1,300 sports medicine
specialists and practitioners will receive leading research and
education programming in a variety of formats from elite orthopedic
sports medicine experts.
Company-Sponsored Booth
- Exhibition of Anika’s HA-based Bone Repair Therapy at booth
#540
About Anika’s Bone Repair Therapy
Anika's bone repair therapy is the Company’s first
surgically-delivered regenerative therapy for bone repair
procedures, and it will be launched in the third quarter of 2019
utilizing Anika’s hybrid commercial model. The therapy is an
injectable, HA-based, settable, osteoconductive calcium phosphate
bone substitute material, and it is indicated for filling bone
voids or defects of the skeletal system (i.e., extremities and
pelvis) that are not intrinsic to the stability of bony structure.
It is provided in a kit with two components (an aqueous solution in
a pre-loaded syringe and a dry powder) that must be mixed
intra-operatively using the supplied mixing system to form a
cohesive paste prior to administration.
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc. (NASDAQ: ANIK) is a
global, integrated orthopedic and regenerative medicines company
based in Bedford, Massachusetts. Anika is committed to improving
the lives of patients with degenerative orthopedic diseases and
traumatic conditions with clinically meaningful therapies along the
continuum of care, from palliative pain management to regenerative
tissue repair. The Company has over two decades of global expertise
developing, manufacturing, and commercializing more than 20
products based on its proprietary hyaluronic acid (HA)
technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®,
MONOVISC®, and CINGAL®,
which alleviate pain and restore joint function by replenishing
depleted HA, and HYALOFAST, a solid HA-based
scaffold to aid cartilage repair and regeneration. For more
information about Anika, please visit
www.anikatherapeutics.com.
Forward-Looking Statements
The statements made in the last sentence of the second paragraph
and the first sentence in the section captioned “About Anika’s Bone
Repair Therapy” of this press release, which are not statements of
historical fact, are forward-looking statements within the meaning
of Section 27A of the Securities Act of 1933, as amended, and
Section 21E of the Securities Exchange Act of 1934, as amended.
These statements include, but are not limited to, those relating to
the Company’s plans for the launch of its surgically-delivered bone
repair therapy. These statements are based upon the current beliefs
and expectations of the Company’s management and are subject to
significant risks, uncertainties, and other factors. The Company’s
actual results could differ materially from any anticipated future
results, performance, or achievements described in the
forward-looking statements as a result of a number of factors
including, but not limited to, (i) the Company’s ability to
successfully commence and/or complete clinical trials of its
products on a timely basis or at all; (ii) the Company’s ability to
obtain pre-clinical or clinical data to support domestic and
international pre-market approval applications, 510(k)
applications, or new drug applications, or to timely file and
receive FDA or other regulatory approvals or clearances of its
products; (iii) that such approvals will not be obtained in a
timely manner or without the need for additional clinical trials,
other testing or regulatory submissions, as applicable; (iv) the
Company’s research and product development efforts and their
relative success, including whether we have any meaningful sales of
any new products resulting from such efforts; (v) the cost
effectiveness and efficiency of the Company’s clinical studies,
manufacturing operations, and production planning; (vi) the
strength of the economies in which the Company operates or will be
operating, as well as the political stability of any of those
geographic areas; (vii) future determinations by the Company to
allocate resources to products and in directions not presently
contemplated; (viii) the Company’s ability to successfully
commercialize its products, in the U.S. and abroad; (ix) quarterly
sales volume variation experienced by the Company, which can make
future results difficult to predict and period-to-period
comparisons potentially less meaningful; (x) the Company’s ability
to provide an adequate and timely supply of its products to its
customers; and (xi) the Company’s ability to achieve its growth
targets. Additional factors and risks are described in the
Company’s periodic reports filed with the Securities and Exchange
Commission, and they are available on the SEC’s website at
www.sec.gov. Forward-looking statements are made based on
information available to the Company on the date of this press
release, and the Company assumes no obligation to update the
information contained in this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190711005016/en/
For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung,
781-457-9000 Chief Financial Officer
For Media Inquiries: W2O Group Sonal Vasudev, 917-523-1418
sonal@w2ogroup.com
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anika Therapeutics (NASDAQ:ANIK)
Historical Stock Chart
From Apr 2023 to Apr 2024